- Document Security Systems Inc's DSS subsidiary, DSS Biomedical International, Inc., has completed a $1 million equity investment in Vivacitas Oncology, Inc.
- Vivacitas Oncology focuses on developing new treatment options to treat cancers resistant to currently available therapies.
- Vivacitas candidate AR-67 is a novel lipophilic camptothecin compound. AR-67 has in vitro, Phase I, and Phase II data in multiple solid tumor types and has shown potential improvement in progression-free survival (6-29 months) in glioblastoma patients while significantly reducing severe side effects usually associated with this drug class.
- Price action: DSS shares traded higher by 1.71% at $1.40 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
